Literature DB >> 24325924

Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi.

Maria C Carrillo1, Demetris Patsios2, Ute Wagnetz2, Frances Jamieson3, Theodore K Marras4.   

Abstract

AIM: Mycobacterium xenopi is described with upper lobe cavitation ("fibrocavitary" pattern), whereas the Mycobacterium avium complex (MAC) is described with bronchiectasis and centrilobular nodules ("nodular bronchiectasis"). We retrospectively described and compared computed tomography (CT) chest manifestations of disease caused by MAC and M xenopi.
MATERIALS AND METHODS: We reviewed patients who had either MAC or M xenopi lung disease and who had CTs between January 2002 and December 2003. Clinical data were recorded, and the patterns on chest CTs were categorized as "fibrocavitary," "nodular bronchiectatic," and "unclassified."
RESULTS: There were 74 patients; 50 with MAC and 24 with M xenopi. The patients with MAC were older (mean 69 vs 58 years; P = .007). Patients with M xenopi more often had emphysema (50% vs 20%; P = .02), cavities (46% vs 16%; P = .01), and nodules ≤5 mm (88% vs 58%; P = .02). M xenopi cases more commonly had a fibrocavitary radiologic pattern (33% vs 18%), with no statistically significant difference (P = .24). MAC was more often associated with a nodular bronchiectatic pattern (68% MAC vs 4% M xenopi; P < .0001). Sixty-three percent of patients with M xenopi had a pattern that was predominantly randomly distributed nodules (11/15 [73%]) or consolidation and/or ground-glass opacities (4/15 [27%]).
CONCLUSION: Compared with MAC, patients with M xenopi infection develop more cavities and more nodules, and they less often have a predominant nodular bronchiectatic pattern. Although a predominantly cavitary pattern appears to be more common with M xenopi, the majority of patients with M xenopi had CT patterns of random nodules or consolidation and/or ground-glass opacities rather than classically described findings.
Copyright © 2014 Canadian Association of Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computed tomography; Mycobacterium avium complex; Mycobacterium xenopi

Mesh:

Year:  2013        PMID: 24325924     DOI: 10.1016/j.carj.2013.05.006

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  13 in total

1.  Mortality among patients with pulmonary non-tuberculous mycobacteria disease.

Authors:  M Fleshner; K N Olivier; P A Shaw; J Adjemian; S Strollo; R J Claypool; L Folio; A Zelazny; S M Holland; D R Prevots
Journal:  Int J Tuberc Lung Dis       Date:  2016-05       Impact factor: 2.373

2.  The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Shannon Novosad; Emily Henkle; Kevin L Winthrop
Journal:  Curr Pulmonol Rep       Date:  2015-07-12

3.  Mycobacterium xenopi Genotype Associated with Clinical Phenotype in Lung Disease.

Authors:  Takashi Hirama; Alex Marchand-Austin; Jennifer Ma; David C Alexander; Sarah K Brode; Theodore K Marras; Frances B Jamieson
Journal:  Lung       Date:  2018-01-18       Impact factor: 2.584

4.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

5.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

6.  Frequency and clinical implications of the isolation of rare nontuberculous mycobacteria.

Authors:  Junghyun Kim; Moon-Woo Seong; Eui-Chong Kim; Sung Koo Han; Jae-Joon Yim
Journal:  BMC Infect Dis       Date:  2015-01-09       Impact factor: 3.090

7.  Fatal pulmonary cavitary disease secondary to Mycobacterium xenopi in a patient with sarcoidosis.

Authors:  Omar Abdulfattah; Divya Salhan; Saroj Kandel; Ebad Ur Rahman; Sumit Dahal; Zainab Alnafoosi; Frances Schmidt
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-12-14

8.  Pulmonary Nontuberculous Mycobacteria-Associated Deaths, Ontario, Canada, 2001-2013.

Authors:  Theodore K Marras; Michael A Campitelli; Hong Lu; Hannah Chung; Sarah K Brode; Alex Marchand-Austin; Kevin L Winthrop; Andrea S Gershon; Jeffrey C Kwong; Frances B Jamieson
Journal:  Emerg Infect Dis       Date:  2017-03       Impact factor: 6.883

9.  Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report.

Authors:  Yoshio Okano; Tsutomu Shinohara; Shino Imanishi; Naoki Takahashi; Nobuhito Naito; Takanari Taoka; Naoki Kadota; Fumitaka Ogushi
Journal:  BMC Pulm Med       Date:  2016-06-10       Impact factor: 3.317

10.  Nontuberculous Mycobacterial Infections in a French Hospital: A 12-Year Retrospective Study.

Authors:  Peggy Blanc; Hervé Dutronc; Olivia Peuchant; Frédéric-Antoine Dauchy; Charles Cazanave; Didier Neau; Gaëtane Wirth; Jean-Luc Pellegrin; Philippe Morlat; Patrick Mercié; José-Manuel Tunon-de-Lara; Marie-Sylvie Doutre; Philippe Pélissier; Michel Dupon
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.